From: Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients
 | Hazard Ratio | ||
---|---|---|---|
Estimate | 95% CI | p value** | |
Treatment Groups | |||
SRS* | reference | ||
Surgery + SRS | 0.68 | 0.49-0.94 | 0.020 |
WBRT + SRS | 0.99 | 0.93-1.05 | 0.660 |
Surgery + WBRT + SRS | 0.79 | 0.61-1.02 | 0.070 |
WBRT | 1.94 | 1.37-2.73 | <0.001 |
Surgery + WBRT | 1.04 | 0.76-1.43 | 0.800 |
Age at diagnosis | |||
<65* | reference | ||
≥65 | 1.21 | 0.91-1.62 | 0.190 |
ECOG-PS | |||
0* | reference | ||
1 | 1.07 | 0.58-1.95 | 0.830 |
2 | 1.67 | 1.02-2.72 | 0.040 |
3 | 4.58 | 4.28-4.91 | <0.001 |
4 | 11.26 | 5.98-21.2 | <0.001 |
Primary Tumor Histology | |||
NSCLC* | reference | ||
SCLC | 1.11 | 0.97-1.26 | 0.130 |
Breast | 0.87 | 0.78-0.96 | <0.001 |
Melanoma and Renal-cell | 1.17 | 1.06-1.3 | <0.001 |
Other | 1.41 | 0.95-2.1 | 0.080 |